Comparing blood thinners and treatment length after a heart attack with a stent
Compares prasugrel with ticagrelor, and shorter with longer treatment, after a heart attack.
Plain-language title generated from the registry record
Registry title: Dual Antiplatelet Therapy Strategies After Acute Myocardial Infarction Undergoing PCI: Prasugrel vs Ticagrelor & 12 Months vs 1-3 Months
Key facts
- Where
- Madrid, SpainSee the site
- Phase
- Phase 4
Where in Spain
- Fundación Jiménez Díaz University HospitalMadrid, SpainTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz
- Trial code
- NCT07507500
- Record updated
- 9 September 2026
- Original description
This study is testing different blood-thinning treatment strategies for people who have had a heart attack and were successfully treated with a coronary stent procedure (PCI). All strategies tested are already approved for this condition and used inversally. This study will define which of the approved strategies is the best one.Read full original descriptionShow less
Strategies for Antiplatelet Management Following Acute Coronary Syndrome
This study is testing different blood-thinning treatment strategies for people who have had a heart attack and were successfully treated with a coronary stent procedure (PCI). All strategies tested are already approved for this condition and used inversally. This study will define which of the approved strategies is the best one.
After PCI, patients usually receive two antiplatelet medicines for up to 12 months to help prevent another heart attack or stroke, but this treatment can also increase bleeding risk. This study will compare a shorter course of dual antiplatelet therapy followed by one antiplatelet medicine alone versus the standard 12-month course. In addition, the study will compare two commonly used antiplatelet drugs, prasugrel and ticagrelor. The goal is to find out which strategy best prevents death, heart attack, or stroke while minimizing serious bleeding.
This study is not testing any new intervention, rather comparing approved drugs and approved durations of use.
Inclusion: ≥18 years old; Admitted because of an acute MI (either STEMI or NSTEMI); Invasive management during index admission with successful PCI; Able to consent.
Exclusion: Indication for oral anticoagulation therapy; Prior history of ischaemic or haemorrhagic stroke or transient ischaemic attack; Concomitant use of potent CYP3A inhibitors or inducers; Planned elective surgery that cannot be deferred 12 months before randomization, requiring interruption of antiplatelet therapy; Intolerance, contraindication or known allergy to either aspirin, prasugrel or ticagrelor; Patients with active bleeding or known bleeding disorders; Patients with chronic kidney disease requiring dialysis; Any disorder that may interfere with drug absorption; Any medical condition that, in the investigator´s judgment, would seriously limit life expectancy (less than one year); Patients with known moderate or severe hepatic dysfunction (Child-Pugh Class B or Class C); Known intracranial aneurism, arteriovenous malformation or neoplasm; Pregnancy or current lactation; Active participation in other clinical trials.